Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Monopar filed an 8-K, but it's just the cover page - no juicy details yet.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on October 7, 2024, reporting on events that occurred on the same date. The filing is primarily a cover page and does not contain substantive details about specific business events, financial statements, or exhibits.
Why It Matters
This filing indicates a regulatory update from Monopar Therapeutics, but lacks specific details on the nature of the event reported.
Risk Assessment
Risk Level: low — The filing is a standard procedural document and does not disclose any new material risks or information.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- October 7, 2024 (date) — Date of earliest event reported
FAQ
What specific event triggered this 8-K filing for Monopar Therapeutics?
The filing itself does not specify the event, only that it is a Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, with the earliest event reported on October 7, 2024.
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a notification to the SEC of a material event or change, as required by regulation, but the specific details are not provided in the initial document.
Does this filing contain any financial statements or exhibits?
The filing lists 'Financial Statements and Exhibits' as an item information, but the actual content of these is not detailed in the provided text.
What is Monopar Therapeutics' principal executive office address?
Monopar Therapeutics Inc.'s principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics' securities?
The filing mentions 'Trading Symbol(s)' in relation to securities registered pursuant to Section 12(b) of the Act, but the specific symbol for Monopar Therapeutics is not listed in the provided text.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-10-07 08:00:20
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20241004_8k.htm (8-K) — 25KB
- ex_730055.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-030764.txt ( ) — 176KB
- mnpr-20241007.xsd (EX-101.SCH) — 3KB
- mnpr-20241007_def.xml (EX-101.DEF) — 12KB
- mnpr-20241007_lab.xml (EX-101.LAB) — 15KB
- mnpr-20241007_pre.xml (EX-101.PRE) — 12KB
- mnpr20241004_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 7, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) is now active and recruiting patients with advanced cancers. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated October 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: October 7, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer